VICTORIA, May 7, 2015 /CNW/ - T-Bird Pharma Inc.
(TSXV:TPI) ("T-Bird" or the "Company"), a
pharmaceutical company focused on developing premium quality
medical marijuana products and a licensed producer ("LP") under the
Marihuana for Medical Purposes Regulations (Canada) ("MMPR"), is pleased to announce that
its wholly owned subsidiary Thunderbird Biomedical Inc. has
received a notice from Health Canada dated May 6, 2015 confirming the renewal of its
production license, and including the expansion of
its license to include full authorization to commence medical
marijuana sales.
"We are very excited to have secured our sales license and look
forward to begin servicing medical marijuana patients and executing
on our patient acquisition and commercial roll out strategy.
We can now begin providing Canadian patients with high quality
medicinal marijuana," said Dr. Bin Huang, President and CEO of
T-Bird Pharma Inc. "In addition to our ongoing commitment to
scientific and clinical research, we have spent considerable time
developing quality assurance and customer service systems that will
be cornerstones of our commercialization effort. Securing a
licence to sell represents a significant milestone in our Company's
evolution as we now move towards commercialization."
About T-Bird and Thunderbird
T-Bird Pharma Inc. is the parent company of Thunderbird
Biomedical Inc., a wholly owned private subsidiary formed in
January, 2013. The principal activities of Thunderbird are
the production of marijuana from its Victoria, British Columbia production
facility, as regulated by the Marihuana for Medical Purposes
Regulations (Canada).
Thunderbird obtained a medical marijuana license to undertake the
production of medical marijuana in February
2014, being the fifth company in Canada to obtain such a license.
Thunderbird was acquired by T-Bird in September, 2013.
ON BEHALF OF THE BOARD
"Dr. Avtar Dhillon"
Chairman
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements.
Forward-looking statements include, but are not limited to,
statements with respect to commercial operations, including
production and sales of medical marijuana, anticipated revenues,
projected size of market, quantities of future medical marijuana
production, completion of production facilities and other
information that is based on forecasts of future results, estimates
of amounts not yet determinable and assumptions of management.
T-Bird Pharma Inc. (the "Company") does not intend, and
does not assume any obligation, to update these forward-looking
statements except as required by law. These forward-looking
statements involve risks and uncertainties relating to, among other
things, results of production and sale activities, the Company's
historical experience with medical marijuana operations, uninsured
risks, regulatory changes, availability of production facilities,
timeliness of government approvals and the granting of permits and
licenses, changes in prices, actual operating and financial
performance of facilities, equipment and processes relative to
specifications and expectations. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
SOURCE T-Bird Pharma Inc.